NHS advisor says NICE discounts should be public; Hospira, Cubist begin patent fight over antibiotic;

@FiercePharma: Shire reports an enviable 47% spike in Q4 earnings, thanks to ADHD and rare-disease meds. Release | Follow @FiercePharma

> Patient-access discounts that drugmakers offer to the U.K.'s cost-effectiveness agency should be more transparent, a National Health Service advisor said. Story

> Bayer said it expects approval to launch its new stroke drug Xarelto in China within two years. More

> Hospira ($HSP) asked the FDA to approve its version of the Cubist antibiotic Cubicin, and the branded drugmaker said it plans to sue for patent infringement within the required 45 days. Report

> Elan posted a larger net loss for the fourth quarter, but saw its share of sales of the multiple sclerosis drug Tysabri grow to $270.6 million from $229.4 million. Item

> Hungary's Egis saw sales drop during its fiscal third quarter but managed to hike profits by 14% on cost-cutting and currency effects. Article

> The U.S. auditing watchdog group fined Ernst & Young $2 million in a settlement related to Medicis Pharmaceutical's ($MRX) 2005, 2006 and 2007 financial statements. News

> Ireland plans to offer a 30% tax cut for expatriates in a bid to attract more highly skilled jobs in industries such as biopharma. Story

Biotech News

@FierceBiotech: Soligenix' proprietary vaccine thermostabilization technology passed through preclinical proof-of-concept studies. Release | Follow @FierceBiotech

@JohnCFierce: Celgene pays $15M for front-row seat on Acetylon myeloma program. Article | Follow @JohnCFierce

@FierceMedDev: EU wants more medical device controls after PIP scare. News via @Reuters | Follow @FierceMedDev

@MarkHFierce: A U.S. trial will test umbilical cord stem cells to treat /reverse hearing loss in babies. It worked in mice. More | Follow @MarkHFierce

> Cytomedix snaps up stem cell biotech Aldagen for a bargain price. Story

> Celgene pays $15M for front-row seat on Acetylon myeloma program. Article

> GSK's Slaoui opts for more flexible approach in DPU change-up. Report

Manufacturing News

> Pakistan Supreme Court interjects itself in drug death scandal. News

> Being more like Coca-Cola takes days out of GSK's pharma supply chain. More

> Decision on new GSK plant location to come soon. Item

> ViroPharma responding quickly to FDA delay of Cinryze manufacturing expansion. Piece

CRO News

> AZ's China R&D strategy calls for outsourcing. Item

> Takeda opens new drug development center in China. Article

> Quintiles report highlights the challenge of the 'value proposition.' Report

> AstraZeneca's latest restructuring spurs debate over outsourcing R&D. Story

Vaccines News

> Merck's RotaTeq not linked with bowel problems. More

> Novartis' Bexsero successfully protects vast majority of infants. Article

> Researchers target vaccines for the First Nation. Story

> Hints of a heroin vaccine from Mexico. News

> Bacterial cancer vaccines show glimpses of activity. Piece

And Finally... An off-Broadway comedy, "Rx," satirizes pharmaceutical marketing by featuring a pill for people who hate their jobs. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.